.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Cerilliant
Deloitte
Dow
Medtronic
Accenture
Teva
AstraZeneca
Fuji
Cipla

Generated: June 22, 2017

DrugPatentWatch Database Preview

Deferiprone - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for deferiprone and what is the scope of deferiprone patent protection?

Deferiprone
is the generic ingredient in one branded drug marketed by Apopharma Inc and is included in two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Deferiprone has thirty-eight patent family members in twenty-five countries.

There are four drug master file entries for deferiprone. One supplier is listed for this compound.

Summary for Generic Name: deferiprone

Tradenames:1
Patents:3
Applicants:1
NDAs:2
Drug Master File Entries: see list4
Suppliers / Packagers: see list1
Bulk Api Vendors: see list69
Clinical Trials: see list51
Patent Applications: see list850
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:deferiprone at DailyMed

Pharmacology for Ingredient: deferiprone

Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes7,049,328► Subscribe ► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes8,703,156► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: deferiprone

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0202114► Subscribe
China101933924► Subscribe
South Korea20100135316► Subscribe
Brazil0112280► Subscribe
Germany60138189► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Baxter
US Army
Fish and Richardson
Cerilliant
Harvard Business School
Cantor Fitzgerald
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot